Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855030 | 1.00 | GNAI3 (0.40) | GNAI3GNAO1GNAI1HRH3KEAP1 | |
| SCHEMBL855029 | 1.00 | GNAI3 (0.40) | GNAI3GNAO1GNAI1HRH3KEAP1 | |
| SCHEMBL2441195 | 0.94 | KEAP1 (0.43) | GNAI3GNAO1GNAI1HRH3KEAP1 | |
| SCHEMBL2441151 | 0.94 | KEAP1 (0.43) | GNAI3GNAO1GNAI1HRH3KEAP1 | |
| SCHEMBL15328845 | 0.94 | KEAP1 (0.43) | GNAI3GNAO1GNAI1HRH3KEAP1 | |
| SCHEMBL4035833 | 0.87 | KEAP1 (0.50) | GNAI3GNAO1GNAI1HRH3KEAP1 | |
| SCHEMBL6333888 | 0.85 | — | — | |
| SCHEMBL2446230 | 0.85 | — | — | |
| SCHEMBL2439975 | 0.85 | — | — | |
| SCHEMBL18233685 | 0.84 | KEAP1 (0.39) | HRH3KEAP1SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4644390-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024140850-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-2850058-B1 | 1-(P-TOLYL)CYCLOPROPYL SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2850058-B1 | 1-(P-TOLYL)CYCLOPROPYL SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9284288-B2 | 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-03-15 | — | — | US | disclosed |
| US-9284288-B2 | 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-03-15 | — | — | US | disclosed |
| US-20150141482-A1 | 1-(p-tolyl)cyclopropyl substituted Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141482-A1 | 1-(p-tolyl)cyclopropyl substituted Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141482-A1 | 1-(p-tolyl)cyclopropyl substituted Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2850058-A1 | 1-(P-TOLYL)CYCLOPROPYL SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-03-25 | — | — | EP | disclosed |
| WO-2013171687-A1 | 1-(P-TOLYL)CYCLOPROPYL SUBSTITUTED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | GNAI3 1672/4885GNAO1 592/4885GNAI1 1334/4885 |
| US-20150141482-A1 | 1-(p-tolyl)cyclopropyl substituted Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists | P2RX1, TACR1, ADRA1A | GNAI3 1432/4885GNAO1 466/4885GNAI1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.